Johns Hopkins ABX Guide
Triclabendazole
INDICATIONS
FDA
FDA
Triclabendazole was approved in 2019 for treating fasciola in individuals ≥ 6 years.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: December 11, 2022
Citation
Dzintars, Kathryn, and Paul G Auwaerter. "Triclabendazole." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540674/all/Triclabendazole.
Dzintars K, Auwaerter PG. Triclabendazole. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540674/all/Triclabendazole. Accessed November 25, 2024.
Dzintars, K., & Auwaerter, P. G. (2022). Triclabendazole. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540674/all/Triclabendazole
Dzintars K, Auwaerter PG. Triclabendazole [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 November 25]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540674/all/Triclabendazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Triclabendazole
ID - 540674
A1 - Dzintars,Kathryn,PharmD, BCPS
AU - Auwaerter,Paul,M.D.
Y1 - 2022/12/11/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540674/all/Triclabendazole
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
